Citations

Showing 10 of 108104 citations.

NIMG-23. DEEP LEARNING FOR ACCURATE, RAPID, FULLY AUTOMATIC MEASUREMENT OF BRAIN TUMOR-ASSOCIATED ABNORMALITY SEEN ON MRI
Mitchell, J. Ross , Singleton, Kyle , Whitmire, Scott A., Clark-Swanson, Kamala , Rickertsen, Cassandra , Hu, Leland , Swanson, Kristin R. , Swanson, Kristin R , Kamnitsas, Konstantinos , Glocker, Ben

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi180-vi181

10.1093/neuonc/noy148.749 Get It

TMOD-07. LOCALIZATION OF ERLOTONIB RELATIVE TO MRI-BASED TUMOR EXTENT IN PDX GLIOBLASTOMA MODEL: TOWARDS A MATHEMATICAL MODEL FOR THE INTERFACE BETWEEN MRI AND DRUG DISTRIBUTION
Jackson, Pamela , Ranjbar, Sara , Randall, Elizabeth C., Lopez, Begona, Hu, Leland , Regan, Michael S. , Abdelmoula, Walid M. , Lopez, Begona, Massey, Susan Christine , He, Lihong , Macura, Slobodan , Agar, Jeffrey N. , Sarkaria, Jann N. , Agar, Nathalie Y.R. , Swanson, Kristin R

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi269-vi270

10.1093/neuonc/noy148.1120 Get It

CMET-47. CLINICAL EVALUATION OF FITNESS TO DRIVE IN PATIENTS WITH BRAIN METASTASES
Vora, Sujay A., Ashman, Jonathan B. , Daniels, T.B., Halyard, Michele Y. , Rule, William G., Butterfield, Richard , Sharma, Akanksha , Mrugala, Maciej , Porter, Alyx B. , Valencia-Sánchez, Cristina , Schild, Steven E. , Zhang, Nan

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi63-vi63

10.1093/neuonc/noy148.256 Get It

GENE-20. A NOVEL K-M ENHANCER REGULATES TEMOZOLOMIDE RESISTANCE AND TUMOR GROWTH IN GLIOBLASTOMA
Chen, Xiaoyue , Gan, Haiyun , Fang, Dong, Kitange, Gaspar J. , Hu, Zeng, Chen, Xiaoyue, Zhang, Minjie , Lee, Jeong‐Heon , Fang, Dong, He, Lihong , Zhang, Zhiguo , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi107-vi107

10.1093/neuonc/noy148.446 Get It

TMOD-18. THE PATIENT DERIVED XENOGRAFT NATIONAL RESOURCE: A COMPREHENSIVE COLLECTION OF HIGH-GRADE GLIOMA MODELS FOR PRE-CLINICAL AND TRANSLATIONAL STUDIES
Tian, Shulan , Peng, Sen, Carlson, Brett L. , Kitange, Gaspar J. , Evers, Lisa, Decker, Paul A. , Kosel, Matthew , Klee, Eric W. , James, C. David , Eckel‐Passow, Jeanette E. , Verhaak, Roel G.W. , Jenkins, Robert B. , Vaubel, Rachael A. , Remonde, Dioval , Schroeder, Mark A. , Kollmeyer, Thomas M. , Mladek, Ann C. , Daniel, J. , Decker, Paul A. , Berens, Michael E. , Califano, Andrea , Lachance, Daniel Honore , Sulman, Erik P. , Tran, Nhan L. , Giannini, Caterina , Parney, Ian F. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi272-vi272

10.1093/neuonc/noy148.1130 Get It

A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)
Fox, Elizabeth , Turpin, Brian , Goldstein, Stuart L. , Liu, Xiaowei , Kudgus, Rachel A. , Weigel, Brenda J. , Reid, Joel M. , Geller, James I. , Minard, Charles G. , Berg, Stacey L.

Mayo Clinic

Cancer | November 5, 2018 | Volume: 124 | Issue: 23 | Pages: 4548-4555

10.1002/cncr.31725 | PMID 30394521 Get It

Abstract Background Axitinib is an oral small molecule that inhibits receptor tyrosine kinases vascular endothelial growth factor receptors 1 to 3. A phase 1 and pharmacokinetic (PK) trial evaluating axitinib was conducted in children with refractory solid tumors. Methods Axitinib was administered orally twice daily in continuous 28‐day cycles. Dose levels (2.4 mg/m 2 /dose and 3.2 mg/m 2 /dose) were evaluated using a rolling 6 design. Serial PKs (cycle 1, days 1 and 8) and exploratory biomarkers were analyzed. Results A total of 19 patients were enrolled; 1 patient was ineligible due to inadequate time having elapsed from prior therapy. The median age of the patients was 13.5 years (range, 5‐17 years). Two of 5 patients who were treated at dose level 2 experienced dose‐limiting toxicities (palmar‐plantar erythryodysesthesia syndrome in 1 patient and intratumoral hemorrhage in 1 patient). Frequent (>20%) grade 1 to 2 toxicities during cycle 1 included anemia, anorexia, fatigue, diarrhea, nausea, and hypertension. Nonhematological toxicities of grade ≥3 in subsequent cycles included hypertension and elevated serum lipase. PK analysis demonstrated variability in axitinib exposure, the median time to peak plasma concentration was 2 hours, and the half‐life ranged from 0.7 to 5.2 hours. Exposure and dose were not found to be significantly associated with hypertension. Five patients achieved stable disease for ≥6 cycles as their best response, including patients with malignant peripheral nerve sheath tumor (1 patient), Ewing sarcoma (1 patient), hepatocellular carcinoma (1 patient), and osteosarcoma (2 patients). One patient with alveolar soft part sarcoma achieved a partial response. Kidney injury biomarkers were found to be elevated at baseline; no trends were identified. Conclusions In children with refractory solid tumors, the maximum tolerated and recommended dose of axitinib appears to be 2.4 mg/m 2 /dose, which provides PK exposures similar to those of adults.
ANGI-02. A CRITICAL ROLE FOR LARG IN RhoC MEDIATED GLIOBLASTOMA CELL INVASION
Dong, Zhiwan , Ensign, Shannon P. Fortin , Sabit, Hemragul, Ruggieri, Rosamaria, Symons, Marc , Loftus, Joseph C. , Ensign, Shannon P. Fortin , Ding, Zonghui , Yang, Yuping , Nakada, Mitsutoshi , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi28-vi28

10.1093/neuonc/noy148.104 Get It

STEM-28. TISSUE FACTOR PROMOTES THE GLIOMA STEM CELL PHENOTYPE, AND IS SUPPRESSED BY MUTANT IDH1
Mirkov, Snezana, Wray, Brian, Lamano, Jonathan B., James, C. David , Unruh, Dusten , Scholtens, Denise M. , Sarkaria, Jann N. , Horbinski, Craig

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi249-vi249

10.1093/neuonc/noy148.1035 Get It

Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance)
Kutny, Matthew A. , Geyer, Susan, Laumann, Kristina, Gregory, John , Powell, Bayard L., Feusner, James H., Laumann, Kristina M, Willman, Cheryl L. , Stock, Wendy , Larson, Richard A.

Mayo Clinic

Pediatric Blood & Cancer | November 5, 2018 | Volume: 66 | Issue: 3 | Pages: No page available

10.1002/pbc.27542 | PMID 30393935 Get It

AbstractBackgroundAcute promyelocytic leukemia (APL) is a unique leukemia subtype requiring specialized treatment including all‐trans retinoic acid (ATRA). A prior report demonstrated worse outcome among young children <5 years old compared with older children.MethodsWe evaluated outcomes for pediatric patients (<18 years old; N = 83) with APL treated on North American intergroup study CALGB 9710 at Children's Oncology Group sites. Induction and consolidation included ATRA, cytarabine, and anthracyclines. Patients ≥15 years old were randomized to addition of arsenic trioxide (ATO) consolidation. All patients were randomized to ATRA maintenance with versus without oral chemotherapy.ResultsThe estimated 5‐year overall survival (OS) rate was 82%, and the event‐free survival (EFS) rate was 54%. Seven patients (8.4%) died during induction due to coagulopathy. Maintenance randomization demonstrated that addition of oral chemotherapy to ATRA significantly reduced relapse rate, but difference in EFS did not reach statistical significance (P = 0.12; 5‐year rates [95% CI]: 41% [17%–64%] ATRA only vs 72% [56%–88%] ATRA plus chemotherapy). There was no difference (P = 0.93) in EFS for age <5 years versus 5–12.99 years versus 13–17.99 years (5‐year rates: 56%, 47%, and 45%, respectively). Among adolescents 15–17.99 years old in the ATO randomization, there was a significantly lower relapse risk at 5 years for those receiving ATO (0% ATO vs 44% no ATO; P = 0.02).ConclusionOur data demonstrate that intensified ATRA, cytarabine, and anthracycline chemotherapy is effective for pediatric APL including very young patients, but early deaths and relapses remain barriers to cure. Further improvements are likely with incorporation of ATO into pediatric APL regimens.
10-Year Epidemiology of Ankle Injuries in Men’s and Women’s Collegiate Basketball
Hartigan, David E. , Makovicka, Justin L. , Patel, Karan A. , Patel, Karan , Tummala, Sailesh V , Tummala, Sailesh V. , Chhabra, Anikar

Mayo Clinic

Orthopaedic Journal of Sports Medicine | November 5, 2018 | Volume: 6 | Issue: 11 | Pages: No page available

10.1177/2325967118805400 | PMID 30480010 Get It

Background: Ankle injury is the most common injury in men’s and women’s basketball, regardless of the level of competition. Purpose: To use the National Collegiate Athletic Association (NCAA) Injury Surveillance Program/System (ISP/ISS) to review the 10-year epidemiology of ankle injuries in men’s and women’s collegiate basketball players. Study Design: Descriptive epidemiology study. Methods: The NCAA ISP was queried for men’s and women’s collegiate basketball ankle injury data from the 2004 through 2014 academic years. Ankle injury rates were calculated based on injuries per athlete-exposure (AE). Injury proportion ratios (IPRs) were determined by comparing variables between sexes. Activity and position of injury were also studied. Results: Over the 10-year study period, most ankle injuries in collegiate basketball occurred in the preseason (female, 1.45/1000 AEs; male, 2.00/1000 AEs), were contact related (female, 50.4%; male, 57.6%), were treated conservatively (female, 98.5%; male, 99.3%), and were new injuries (female, 78.0%; male, 78.9%), resulting in a time loss of less than 7 days (female, 62.7%; male, 65.2%). The most common injury types were lateral ligament complex tears (female, 83.5%; male, 80.0%), deltoid ligament tears (female, 5.6%; male, 7.2%), and high ankle sprains (female, 7.1%; male, 7.0%). Guards experienced the highest rate of ankle injuries in competition (female, 50.1%; male, 43.3%), and rebounding was found to be the most common activity during an injury (female, 30.3%; male, 34.4%). The rate of ankle injuries was significantly lower in women than in men (IPR, 0.81 [95% CI, 0.75-0.88]). Conclusion: This study found that most ankle injuries in collegiate basketball occurred during the preseason, were contact related, were treated conservatively, and were new injuries that resulted in a time loss of less than 7 days.